A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Motolimod (Primary) ; Carboplatin; Cetuximab; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Laryngeal cancer; Oesophageal cancer; Pharyngeal disorders; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ACTIVE-8
  • Sponsors VentiRx Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint (To compare the efficacy of VTX-2337 plus SOC to SOC alone in prolonging the PFS of patients with recurrent or metastatic SCCHN) has not been met according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top